Use of beta-blocker is associated with lower mortality in patients with coronary artery disease with or without COPD.
Clin Respir J. 2018 Oct 01;:
Authors: Sheikh Rezaei S, Rinner C, Ratajczak P, Grossmann W, Gall W, Wolzt M
INTRODUCTION: Beta-blockers are indicated for secondary prevention of coronary artery disease (CAD). However, in patients with co-morbidity of chronic obstructive pulmonary disease (COPD) an under-use of beta-blocker has been reported.
MATERIALS AND METHODS: Prescription and demographic data and information on hospital discharge diagnoses from 13 Austrian health insurance funds for the years 2006 to 2007 were analysed. The primary end point was all-cause mortality of patients with CAD with or without COPD and its association with use of beta-blockers.
RESULTS: In 2006 and 2007, 65717 patients (37% female, 63% male) were discharged with a diagnosis of CAD. Among these patients, 46% had a co-diagnosis of COPD, 24% had diabetes, and 75% received beta-blockers. Use of beta-blockers was comparable in CAD patients with COPD and without COPD with 77% and 74%, respectively. 1872 (8.1%) and 1473 (5.6%) patients with and without COPD, who used beta-blockers died within month months in 2006 and 2007. 1553 (22.0%) and 1862 (22.2%) of patients with and without COPD and without beta-blockers died during the corresponding time period.
DISCUSSION: Use of beta-blockers was similar in patients with CAD with or without co-diagnosis of COPD. However, mortality of beta-blocker users was markedly lower than that of non-users in patients with CAD with or without COPD. This article is protected by copyright. All rights reserved.
PMID: 30276967 [PubMed - as supplied by publisher]